The munKNEE Psychedelic Drug Stocks Index tracks the six (6) largest psychedelic stocks, by market capitalization, that research the treatment of mental illnesses based on the use of one or more of ten (10) different psychedelic substances (read 10 Psychedelic Substances And The 36 Companies Researching Them). Below are their performances last week and YTD:

1. Compass Pathways* (CMPS): UP 30.3% last week; UP 22.2% YTD
   • Is focused on the development of psilocybin therapy for people with Treatment-Resistant Depression.
2. Mind Medicine (MNMD): UP 23.9% last week; UP 50.0% YTD 
   • Is focused on discovering, developing, and deploying therapies to address addiction and mental illness development.
3. Seelos** (SEEL): UP 16.7% last week; UP 40.0% YTD
   • Is focused on developing products for the treatment of Central Nervous System disorders and other rare disorders.
4. Cybin** (CYBN): UP 15.4% last week; UP 55.2% YTD
   • Is focused on utilizing proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches, and treatment regimens for psychiatric disorders.
5. Atai* (ATAI): DOWN 1.1% last week; DOWN 30.2% YTD 
   • Is focused on acquiring and developing treatments that lead to paradigm shifts in the mental health space.
6. GH Research* (GHRS): UP DOWN 4.2% last week; UP 1.3% YTD
   • Is focused on developing 5-MeO-DMT therapies for the treatment of patients with Treatment-Resistant Depression.

In total, the Index went UP 11.3% last week and is now UP 11.2% YTD.

* These three companies have market capitalizations in excess of $400M and are constituents in munKNEE's  My "Rags-to-Riches" Portfolio for 2023; articles tracking its performance should commence the third week of January, 2023. **These two companies have market capitalizations of $100M and are constituents in munKNEE's  A Multi-bagger" Portfolio for 2023; articles tracking its performance will commence the third week of January, 2023.

Six (6) other psychedelic companies (see details here) are primarily focused on the development, expansion, and operation of ketamine-assisted therapy (KAT) clinics hoping to capitalize on the massive commercial opportunity that exists to treat the two billion people worldwide who suffer from chronic pain, addiction, substance abuse withdrawal, and depression. All are highly speculative investments and penny stocks with tiny market capitalization. They are as follows, in alphabetical order:

1. Awakn Life Sciences Corp.  (NEO: AWAKN|OTCQB: AWKNF);
2. Delic Corp. (CSE: DELC|OTCQB: DELCF);
3. Field Trip Health and Wellness Ltd. (TSXV: FTHW|OTCQB: FTHWF);
4. Numinus Wellness Inc. (TSX: NUMI|OTCQX: NUMIF);
5. Revitalist Lifestyle and Wellness Ltd. (CSE: CALM|OTCQB: RVLWF);
6.  Universal Ibogaine Inc. (TSXV: IBO|OTCQB: IBOGF)

The above psychedelic-assisted therapy clinic stocks went UP 3.6%, on average, last week and are now UP 13.7% YTD.

More By This Author:

Largest Cannabis LPs Up 8% This Week; Now +13% YTD
A "Multi-Bagger" Portfolio For 2023 - Introduction
Organigram Reports A Net Profit In Q1